Skip to content

Study · Non-randomized trial · n = 16 · 2018

4 results

The effects of adjunctive intranasal oxytocin in patients with schizophrenia.

Ota M, Yoshida S, Nakata M, Yada T, Kunugi H

Postgraduate medicine6 Nov 2017Cited by 17 (Europe PMC)

PMID29105546 (opens in a new tab)DOI10.1080/00325481.2018.1398592 (opens in a new tab)PepBankPUB-29105546
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese patients with chronic schizophrenia, intranasal oxytocin significantly reduced positive and negative syndrome scale scores.

    In plain wordsIn Japanese people with chronic schizophrenia, intranasal oxytocin lowered symptom scores over three months.

    Peptide
    Oxytocin
    Outcome
    DecreasePANSS scores
    Study

    n = 16

    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Oxytocin significantly reduced scores on the positive and negative syndrome scale
    1 context sentence
    Summary · context
    Subjects were 16 chronic schizophrenia patients who underwent intranasal oxytocin treatment for 3 months and were assessed for changes in severity of clinical symptoms and cognitions.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese patients with chronic schizophrenia, intranasal oxytocin reduced scores especially on the negative symptoms.

    In plain wordsIn Japanese people with chronic schizophrenia, intranasal oxytocin lowered scores for negative symptoms.

    Peptide
    Oxytocin
    Outcome
    DecreasePANSS negative symptom score
    Study

    n = 16

    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Oxytocin significantly reduced scores on the positive and negative syndrome scale, especially on the negative symptoms.
    1 context sentence
    Summary · context
    Subjects were 16 chronic schizophrenia patients who underwent intranasal oxytocin treatment for 3 months and were assessed for changes in severity of clinical symptoms and cognitions.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Japanese patients with chronic schizophrenia, verbal fluency improved after intranasal oxytocin.

    In plain wordsIn Japanese people with chronic schizophrenia, verbal fluency improved after intranasal oxytocin.

    Peptide
    Oxytocin
    Outcome
    IncreaseVerbal fluency
    Study

    n = 16

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    As for cognition, there was an improvement of the verbal fluency.
    1 context sentence
    Summary · context
    Subjects were 16 chronic schizophrenia patients who underwent intranasal oxytocin treatment for 3 months and were assessed for changes in severity of clinical symptoms and cognitions.
  4. 04HumanNon-randomized trialMechanism

    In patients with chronic schizophrenia given intranasal oxytocin, the change in the negative score correlated negatively with gray matter volume of the right insula and left cingulate cortex.

    In plain wordsIn people with chronic schizophrenia given intranasal oxytocin, gray matter volume in two brain areas was linked to the fall in negative symptom scores.

    Peptide
    Oxytocin
    Outcome
    Not applicableNegative symptom change and gray matter volume
    Study

    n = 15

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Furthermore, the change of the negative score in positive and negative syndrome scale showed a negative correlation with the gray matter volumes of the right insula and left cingulate cortex.
    1 context sentence
    Summary · context
    Fifteen of the 16 subjects underwent 3-Tesla magnetic resonance imaging.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.